This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Emergent BioSolutions Inc. (EBS)
Wedbush 2012 Life Sciences Management Access Conference Call
August 14, 2012 8:00 am ET
R. Don Elsey – Senior Vice President-Finance & Administration, Chief Financial Officer and Treasurer
Christopher N. Marai – Wedbush Securities, Inc.
PresentationChristopher N. Marai – Wedbush Securities, Inc.
Okay, hello good morning. My name is Chris Marai. I’m an analyst here at Wedbush Securities with Greg Wade and David Nierengarten. We’re part of the life science and biotechnology team. And it’s my pleasure to introduce to you today the CFO of Emergent Biosolutions, Don Elsey. He will be telling us a little bit about Emergent’s growing pipeline as well as their BioThrax franchise. Great, thank you Don.
R. Don Elsey
Thank you very much. Good morning to the hearty souls who have made it here so bright and early and I know seats are at premium. So let’s just jump in and get started the typical forward-looking statement where we are going to make some forward-looking statements and actual results may differ from those statements.
So I want to jump in with basically a company overview today. And if you take a look at Emergent just at a glance, we’ve got a proven cash generator in BioThrax, the only anthrax vaccine that’s licensed today. We’ve got two value-creating businesses, were organized into BioDefense and BioSciences. We will get into the structure and the focus of those businesses in a little bit.